文献速递MDS 与骨髓增殖性肿瘤

REALISE II期研究:芦可替尼新型给药方案治疗贫血性骨髓纤维化的疗效与安全性

Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study.
PubMed 文献 · Leukemia · 2021-05-20

Anemia is a frequent manifestation of myelofibrosis (MF) and there is an unmet need for effective treatments in anemic MF patients.…

要点

  • 减量起始芦可替尼(10mg bid 12周后按疗效和血小板计数加量至25mg bid)在贫血MF患者中脾脏应答率70%。
  • 最常见剂量中断/调整原因为血小板减少(17.6%)和贫血(11.8%)。
  • 血红蛋白中位水平稳定,输血需求较基线未增加,无需因贫血延迟或停用芦可替尼。

核心结论

  • 在贫血性骨髓纤维化患者中,芦可替尼减量起始并延迟加量的策略可有效缩脾,且不加重贫血或增加输血需求。

主要发现

  • 70%的患者在研究期间任意时间点实现可触及脾脏长度缩小≥50%。
  • 导致剂量中断/调整的最常见不良事件为血小板减少(17.6%)和贫血(11.8%)。
  • 血红蛋白中位水平保持稳定,输血需求较基线未增加。
  • 基线时脾脏更大且白细胞计数更高的患者接受了剂量增加。

关键数值与推荐

  • 起始剂量为芦可替尼10 mg每日两次,前12周给药,之后根据疗效和血小板计数允许加量至最高25 mg每日两次。
  • 入组患者中位年龄67岁(范围45-88),女性占41.2%,18%为输血依赖。

临床怎么用

  • 对于合并贫血的骨髓纤维化患者,无需因贫血或治疗中出现贫血而延迟或停用芦可替尼,可采用减量起始并延迟加量的策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Anemia is a frequent manifestation of myelofibrosis (MF) and there is an unmet need for effective treatments in anemic MF patients. The REALISE phase 2 study (NCT02966353) evaluated the efficacy and safety of a novel ruxolitinib dosing strategy with a reduced starting dose with delayed up-titration in anemic MF patients. Fifty-one patients with primary MF (66.7%), post-essential thrombocythemia MF (21.6%), or post-polycythemia vera MF (11.8%) with palpable splenomegaly and hemoglobin <10 g/dl were included. Median age was 67 (45-88) years, 41.2% were female, and 18% were transfusion-dependent. Patients received 10 mg ruxolitinib b.i.d. for the first 12 weeks, then up-titrations of up to 25 mg b.i.d. were permitted, based on efficacy and platelet counts. Overall, 70% of patients achieved a ≥50% reduction in palpable spleen length at any time during the study. The most frequent adverse events leading to dose interruption/adjustment were thrombocytopenia (17.6%) and anemia (11.8%). Patients who had a dose increase had greater spleen size and higher white blood cell counts at baseline. Median hemoglobin levels remained stable and transfusion requirements did not increase compared with baseline. These results reinforce the notion that it is unnecessary to delay or withhold ruxolitinib because of co-existent or treatment-emergent anemia.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Cervantes F, Ross DM, Radinoff A, et al. Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study. Leukemia. 2021. PMID: 34017073. doi:10.1038/s41375-021-01261-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。